Importantly, it was the first phase 3 study to report improved OS and PFS in combined treatment (anti-PD-1 + small molecule TKI) vs. TKI for unresectable HCC in the first-line setting. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.